Aberrant activation of the PI3K/Akt/mTOR pathway is a hallmark of lymphomas, including Hodgkin lymphoma (HL) (59, 60) and non-Hodgkin lymphomas (NHLs) (61, 62). This evidence concerns the gene AKT1 and lymphoma.